Breathefree Lanka Private Limited Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: Breathefree Lanka Private Limited Pharmaceutical Import Records from India — 17 Products, $37.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Breathefree Lanka Private Limited — Pharmaceutical Importer Profile (2026) | 17 Products, $37.1M Trade | TransData Nexus

Breathefree Lanka Private Limited

Pharmaceutical Importer · Sri Lanka · Respiratory Focus · $37.1M Total Trade · DGFT Verified

Breathefree Lanka Private Limited is a pharmaceutical importer based in Sri Lanka with a total trade value of $37.1M across 17 products in 8 therapeutic categories. Based on 968 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Breathefree Lanka Private Limited sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Breathefree Lanka Private Limited — Import Portfolio & Supplier Network

Breathefree Lanka Private Limited import network — 17 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Breathefree Lanka Private Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$8.6M	841	100.0%

Breathefree Lanka Private Limited sources from 1 verified Indian supplier across 345 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Breathefree Lanka Private Limited Import?

Formulation	Value	Ships
Zaart 50 tablets losartan potassium	$653.2K	14
Asthalin inhaler/dose counter	$242.2K	7
Amlopres 5 tablet amlodipine	$230.0K	10
Asthalin 400 dp CAPS salbutamol	$169.6K	8
Atorlip 20 tablets atorvastatin	$168.1K	6
Seroflo 250 inhaler fluticasone propionate 250 MCG and salmeterol xinafoate 25mcg	$150.0K	3
Azee 500MG tablet (azithromycin dihydrate) 33267 Pack 10 x	$150.0K	3
Silagra 100 TAB ( violet colour) (sildenafil citrate 100 MG) . (inv.qty.19554 Pack 10x1x4s=782160 nos	$141.5K	3
Atorlip 10 tablets atorvastatin	$136.6K	3
Cephadex 500 CAPS cephalexin capsules 500 MG . inv.qty.7320 Pack 10x10s=732000	$128.3K	3
Tiova hfa inhaler tiotropium bromide	$127.4K	4
Foracort400 dp CAPS (formoterol fumarate6mcg+budesonide 400mcg rota) (inv.qty.19628 Pack 10x10s=1962800 nos	$123.9K	3
Foracort400 dp CAPS (formoterol fumarate6mcg+budesonide 400mcg rota) (inv.qty.19575 Pack 10x10s=1957500 nos	$123.6K	3
Pirfenex 200 tablets (pirfenidone) 16200pack 3 x	$121.7K	3
Foracort400 dp CAPS (formoterol fumarate6mcg+budesonide 400mcg rota) 18727 pack10 x	$118.1K	3

Import Portfolio — Top 17 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Cephalexin	Antibiotics	$6.8M	135	1.9%	6
2	Salbutamol	Respiratory	$4.9M	140	3.3%	4
3	Losartan	Cardiovascular	$4.6M	92	1.5%	2
4	Formoterol	Respiratory	$4.2M	89	5.7%	4
5	Montelukast	Respiratory	$3.4M	67	2.0%	3
6	Budesonide	Respiratory	$3.0M	65	1.2%	8
7	Salmeterol	Respiratory	$2.1M	64	2.8%	7
8	Azithromycin	Antibiotics	$2.0M	41	1.1%	10
9	Potassium	Nutritional Supplements	$2.0M	41	0.3%	13
10	Cefuroxime	Advanced Antibiotics	$1.4M	79	1.1%	14
11	Telmisartan	Cardiovascular	$1.1M	22	0.0%	17
12	Tiotropium	Respiratory	$421.3K	16	0.4%	8
13	Meloxicam	Analgesics & Antipyretics	$344.0K	40	0.2%	12
14	Ipratropium	Respiratory	$279.2K	17	0.5%	13
15	Torsemide	Diuretics	$250.8K	27	1.4%	10
16	Miconazole	Antifungals	$218.9K	20	1.1%	12
17	Warfarin	Cardiovascular	$130.0K	13	1.8%	12

Breathefree Lanka Private Limited imports 17 pharmaceutical products across 8 categories into Sri Lanka totaling $37.1M.

Breathefree Lanka Private Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Breathefree Lanka Private Limited is a pharmaceutical importer and distributor based in Colombo, Sri Lanka. Established in 2015, the company specializes in sourcing and supplying a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, to meet the healthcare needs of the Sri Lankan market. With a focus on quality and affordability, Breathefree Lanka collaborates with reputable international manufacturers to ensure the availability of essential medicines. The company's operations are guided by a commitment to regulatory compliance and ethical standards, aiming to enhance the health and well-being of the Sri Lankan population.

2Distribution Network

Breathefree Lanka Private Limited operates a centralized distribution model from its headquarters in Colombo, Sri Lanka. The company maintains a well-organized logistics system to ensure timely delivery of pharmaceutical products across the island. While specific warehouse locations are not publicly disclosed, the company's strategic positioning in Colombo facilitates efficient access to major transportation routes, including the Port of Colombo, which is a key hub for international trade. This centralization allows Breathefree Lanka to effectively manage inventory and distribution, ensuring that healthcare providers nationwide receive the necessary pharmaceutical supplies promptly.

3Industry Role

In Sri Lanka's pharmaceutical supply chain, Breathefree Lanka Private Limited functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from international suppliers, particularly from India, and supplies them to various stakeholders within the healthcare sector, including hospitals, clinics, pharmacies, and government health services. By bridging the gap between international manufacturers and local healthcare providers, Breathefree Lanka plays a crucial role in ensuring the availability of essential medicines in the Sri Lankan market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Breathefree Lanka Private Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Breathefree Lanka Private Limited demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports exclusively from a single supplier, Cipla Limited, India. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and potentially leverage favorable terms with a major supplier. However, this approach also exposes the company to risks associated with supplier disruptions, such as production delays or regulatory issues affecting Cipla Limited. The stability of this relationship is crucial; any significant issues with Cipla Limited could impact Breathefree Lanka's ability to meet the pharmaceutical needs of the Sri Lankan market.

2Supply Chain Resilience

The resilience of Breathefree Lanka Private Limited's supply chain is closely tied to its exclusive partnership with Cipla Limited. While this relationship offers streamlined operations, it also means that the company lacks alternative suppliers to mitigate potential disruptions. The diversity of formulations imported—spanning 17 products across 8 therapeutic categories—provides some buffer against market fluctuations. However, the company's reliance on a single supplier for all its imports makes it vulnerable to any operational or regulatory challenges faced by Cipla Limited. Ensuring that Cipla Limited adheres to international quality standards and maintains consistent supply capabilities is essential for Breathefree Lanka's supply chain resilience.

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

In Sri Lanka, the National Medicines Regulatory Authority (NMRA) serves as the primary regulatory body overseeing the pharmaceutical sector. Established under the NMRA Act No. 05 of 2015, the NMRA is responsible for ensuring the availability of efficacious, safe, and good-quality medicines to the public at affordable prices. The authority regulates and evaluates medicinal products, devices, and manufacturing facilities, and is tasked with issuing wholesale licenses, retail licenses, and transport licenses for medicinal products and devices. Additionally, the NMRA controls the pricing for selected drugs and devices in the Sri Lankan market and oversees the registration and certification procedures for medicines.

2Import Licensing & GMP

To import pharmaceutical products into Sri Lanka, companies must obtain the necessary import licenses from the NMRA. This process involves registering with the NMRA, submitting an official application form with product details, and providing supporting documentation such as the Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (COA), Batch Release Certificate, and Product Registration Certificate, if applicable. The NMRA evaluates these submissions to ensure compliance with Sri Lankan import standards. Regarding Good Manufacturing Practice (GMP) certification, the NMRA recognizes certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized authorities to meet regulatory requirements.

Breathefree Lanka Private Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Breathefree Lanka Private Limited's product strategy focuses on importing pharmaceutical formulations across multiple therapeutic categories, including respiratory, antibiotics, and cardiovascular drugs. This diversified approach allows the company to address a broad spectrum of healthcare needs in Sri Lanka. The market demand for these products is driven by the prevalence of respiratory conditions, infectious diseases, and cardiovascular ailments among the Sri Lankan population. By focusing on these therapeutic areas, Breathefree Lanka aims to provide essential medicines that improve patient outcomes and contribute to public health.

2Sourcing Profile

Breathefree Lanka Private Limited primarily sources generic pharmaceutical formulations from India, leveraging the country's robust pharmaceutical manufacturing capabilities and cost-effectiveness. The company's sourcing strategy emphasizes a diverse range of formulations to meet various therapeutic needs. India's established reputation for producing high-quality generic medicines aligns with Breathefree Lanka's commitment to providing affordable and effective healthcare solutions in Sri Lanka.

3Market Positioning

Seller's Guide — How to Become a Supplier to Breathefree Lanka Private Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Breathefree Lanka Private Limited. The company's current sourcing strategy, which relies exclusively on Cipla Limited, presents an opportunity to diversify its supplier base, thereby enhancing supply chain resilience and reducing dependency on a single source. Indian exporters can approach Breathefree Lanka by demonstrating compliance with NMRA regulations, offering competitive pricing, and ensuring consistent product quality. Establishing such partnerships could lead to a more robust and flexible supply chain, benefiting both parties.

2Requirements & Qualifications

Indian exporters seeking to supply Breathefree Lanka Private Limited and the Sri Lankan market must ensure compliance with NMRA regulations. This includes obtaining the necessary import licenses, providing required documentation such as the Certificate of Pharmaceutical Product (COPP), Certificate of Analysis (COA), Batch Release Certificate, and Product Registration Certificate, if applicable. Additionally, suppliers must hold valid GMP certifications from recognized authorities, including EU GMP, WHO GMP, or PIC/S, to meet regulatory standards. Adhering to these requirements is essential for establishing a successful partnership with Breathefree Lanka.

Frequently Asked Questions — Breathefree Lanka Private Limited

What products does Breathefree Lanka Private Limited import from India?

Breathefree Lanka Private Limited imports 17 pharmaceutical products across 8 categories. Top imports: Cephalexin ($6.8M), Salbutamol ($4.9M), Losartan ($4.6M), Formoterol ($4.2M), Montelukast ($3.4M).

Who supplies pharmaceuticals to Breathefree Lanka Private Limited from India?

Breathefree Lanka Private Limited sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $8.6M).

What is Breathefree Lanka Private Limited's total pharmaceutical import value?

Breathefree Lanka Private Limited's total pharmaceutical import value from India is $37.1M, based on 968 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Breathefree Lanka Private Limited focus on?

Breathefree Lanka Private Limited imports across 8 categories. The largest: Respiratory (49.1%), Antibiotics (23.7%), Cardiovascular (15.7%).

Get Full Breathefree Lanka Private Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.